GSK India FY26: ₹3,790 Cr Revenue, ₹57 Dividend

FY26 results and dividend recommendation

GlaxoSmithKline Pharmaceuticals Ltd (GSK India) announced its financial results for the fourth quarter and full year ended 31 March 2026, along with a dividend recommendation by its board. The company said its board of directors recommended a final dividend of ₹57 per equity share for the year ended 31 March 2026. Alongside the dividend disclosure, GSK India reported a modest increase in full-year revenue and a sharper improvement in profitability, supported by higher operating margins.

The FY26 update matters for investors tracking how large-cap pharma companies are balancing growth with margin delivery. In GSK India’s case, the headline numbers show relatively steady top-line movement, while profitability metrics improved at a faster pace.

Full-year FY26 performance: revenue up 2%, PAT up 10%

For the full year ended 31 March 2026, GSK India reported revenue of ₹3,790 crore, representing growth of 2%. Profit after tax (PAT) increased by 10% to ₹1,012 crore. The company also reported that EBITDA margins expanded by 290 basis points to 34% for the year.

The combination of low single-digit revenue growth with stronger profit growth typically signals either operating leverage, improved product mix, tighter cost control, or a blend of these factors. The company’s disclosure specifically highlighted margin expansion, which is a key operating indicator watched closely in pharmaceuticals given input costs, trade channels, and compliance-led spending.

Q4FY26 snapshot: higher margin, solid quarterly profit

For the quarter ended 31 March 2026, the company reported revenue of ₹989 crore and PAT of ₹275 crore. EBITDA margins improved by 90 basis points to 35% for the quarter.

Quarterly disclosures like these help investors judge whether full-year margin gains are sustained in the most recent period. In this case, the reported quarterly margin improvement was smaller than the full-year expansion, but the quarter still showed an improvement versus the prior base, as stated by the company.

Dividend: ₹57 per equity share

GSK India said its board recommended a final dividend of ₹57 per equity share for FY26. The announcement provides a clear per-share figure, but the release excerpt does not include additional details such as record date, payment date, or shareholder approval timeline.

For shareholders, the dividend recommendation is a direct cash-return signal. It is also a data point investors often evaluate alongside earnings growth, margin profile, and the company’s stated priorities on portfolio investment.

What GSK India told investors in its November 2025 presentation

The provided material also references a presentation made by GlaxoSmithKline Pharmaceuticals to analysts and investors on 6 November 2025. In that update, the company highlighted “commercial ambition driven by innovation” and “portfolio transformation driving profitability.”

The presentation reported revenue of ₹974 crore with a 34.4% EBITDA margin and a 26.1% PAT margin. It also noted that key brands were competitive, while growth was impacted by market headwinds.

A separate financial summary in the same material listed:

• Revenue: ₹974 crore (growth -2.6%)
• EBITDA: ₹335 crore (margin 34.4%, growth +4.9%)
• PAT: ₹253 crore (margin 26.1%, growth +3.3%)

While revenue growth was negative in that specific snapshot, both EBITDA and PAT showed growth along with improved margins, as reported.

Strategy themes: focus, agility, and innovation

GSK India’s strategy, as described in the investor material, is driven by focus and innovation, and supported by cultural transformation. The presentation framed priorities under three labels:

• Focus: Sharper strategies for key brands to win versus competition.
• Agile: An adaptable approach to expand categories like adult immunization.
• Innovate: Scaling Oncology as the next frontier of innovation.

The emphasis on category expansion and oncology scaling indicates the company is positioning for therapeutic areas where differentiated products and brand strength can influence profitability.

Vaccines performance highlight

Among business highlights, the material stated that the paediatric vaccines portfolio grew by 13%. Vaccines can be a meaningful growth driver in India due to a mix of government programs and private market demand, and the disclosure points to positive traction in that portfolio during the period referenced.

Operational context referenced in analyst commentary

The text also includes a reference to an analyst note stating that revenue growth in one period was negatively impacted by supply-led issues at a CMO, quantified at around ₹40 crore (cited as ~INR 400 million in the note). The same excerpt mentioned a temporary impact from a GST rate cut, but the number in the provided text is incomplete and no unit is clearly specified.

Separately, a company document dated 9 February 2026 referenced that, for “the quarter standalone,” sales were up 2%, EBITDA grew 5%, and PAT growth was 6%.

Key numbers at a glance

Stock snapshot included in the material

The provided dataset also listed the following market metrics for the stock:

Market impact: what investors will track from here

With FY26 revenue growth at 2% and PAT up 10%, the gap between top-line and bottom-line growth puts operating margin performance at the centre of the investment narrative. The full-year EBITDA margin expansion to 34%, along with a Q4 margin of 35%, sets a clear benchmark for assessing sustainability in subsequent quarters.

Investors also tend to monitor how strategy themes discussed in investor forums translate into product-level execution, particularly in categories mentioned in the material such as adult immunization and oncology, and in segments like paediatric vaccines that have shown reported growth.

Conclusion

GSK India’s FY26 update combines a final dividend recommendation of ₹57 per equity share with a year marked by modest revenue growth and stronger profit expansion. The company’s disclosures also underline margin improvement as a key feature of performance. The next set of company communications will be important for additional dividend timelines and for any further detail on business drivers behind the margin expansion.